Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072358 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT00072358: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00072358 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 291 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072358, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Combining monoclonal antibody 3F8 with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining monoclonal antibody 3F8 with sargramostim in treating patients who have neuroblastoma.
Interventions
- BIOLOGICAL anti-GD2 murine IgG3 monoclonal antibody 3F8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2003-07 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072358
The ClinicalTrials.gov registry entry for NCT00072358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-GD2 murine IgG3 monoclonal antibody 3F8 is the first listed.
NCT00072358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072358 about?
NCT00072358 is a clinical study titled "Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma". RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or p...
What is the current status of trial NCT00072358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2003-07. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT00072358?
The interventions under investigation include: anti-GD2 murine IgG3 monoclonal antibody 3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072358?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.